BMC Pharmacology & Toxicology

Scope & Guideline

Connecting global minds through open-access research.

Introduction

Immerse yourself in the scholarly insights of BMC Pharmacology & Toxicology with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN-
PublisherBMC
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationBMC PHARMACOL TOXICO / BMC Pharmacol. Toxicol.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

BMC Pharmacology & Toxicology aims to advance knowledge in the fields of pharmacology and toxicology, focusing on drug action, safety, and therapeutic efficacy. The journal encompasses a wide range of studies related to drug development, pharmacokinetics, pharmacodynamics, and the toxicological assessment of substances.
  1. Pharmacokinetics and Drug Metabolism:
    Research exploring how drugs are absorbed, distributed, metabolized, and excreted in biological systems. This includes studies on population pharmacokinetics and drug-drug interactions.
  2. Toxicological Assessments:
    Investigations into the adverse effects of drugs and chemicals on biological systems, including in vivo and in vitro studies that assess safety and toxicology.
  3. Therapeutic Efficacy and Drug Development:
    Studies evaluating the effectiveness of pharmacological agents in treating various conditions, including comparative studies of drug formulations and dosages.
  4. Adverse Drug Reactions and Pharmacovigilance:
    Research focused on monitoring and analyzing adverse drug reactions, utilizing databases like the FDA Adverse Event Reporting System to improve drug safety.
  5. Innovative Drug Delivery Systems:
    Development and evaluation of novel drug delivery methods, including nanotechnology-based approaches to enhance therapeutic outcomes.
  6. Molecular Mechanisms of Drug Action:
    Exploration of the cellular and molecular pathways affected by drugs, including studies on signaling pathways and gene expression related to pharmacological effects.
BMC Pharmacology & Toxicology has identified several emerging themes and trends within its recent publications. These areas reflect current advancements in pharmacological research and the evolving landscape of drug safety and efficacy assessments.
  1. Integrated Pharmacovigilance Approaches:
    There is an increasing trend towards comprehensive pharmacovigilance studies that leverage big data analytics and real-world evidence to monitor drug safety and adverse reactions.
  2. Personalized Medicine and Pharmacogenomics:
    Research focusing on the genetic factors that influence drug metabolism and response is gaining traction, emphasizing the importance of tailoring treatments to individual patient profiles.
  3. Nanotechnology in Drug Delivery:
    The application of nanotechnology for drug delivery systems is emerging as a significant area of research, aimed at improving the bioavailability and therapeutic efficacy of medications.
  4. Investigating Drug Interactions:
    A growing emphasis on understanding complex drug-drug interactions, particularly in polypharmacy settings, is evident, reflecting the need for safer therapeutic regimens.
  5. Therapeutics in the Context of COVID-19:
    Research addressing the pharmacological management of COVID-19, including the evaluation of existing drugs and the development of novel therapeutic agents, has surged in relevance.
  6. Exploration of Natural Products and Traditional Medicine:
    There is an increasing interest in the pharmacological properties of natural products, with studies assessing their potential therapeutic effects and safety profiles.

Declining or Waning

While BMC Pharmacology & Toxicology has maintained a broad scope, certain themes have shown a decline in prominence over recent years. These waning areas may reflect shifts in research focus or emerging priorities in pharmacological and toxicological studies.
  1. Traditional Toxicology Studies:
    There has been a noticeable reduction in studies focused solely on classical toxicology without integrating modern methodologies such as molecular biology techniques or advanced in vivo models.
  2. In vitro Studies without Clinical Correlation:
    Research that relies exclusively on in vitro models without subsequent validation in clinical or real-world settings is becoming less common, as there is a growing emphasis on translational research.
  3. Single-Agent Pharmacology:
    Research focusing solely on the effects of single drugs is declining, with a shift towards studies that explore drug combinations, polypharmacy, or drug interactions.
  4. Animal Models with Limited Relevance to Human Health:
    The use of animal models that do not adequately mimic human pathophysiology is less favored, leading to a decline in studies employing outdated or less relevant models.
  5. Descriptive Epidemiology of Drug Use:
    Research that simply describes drug use patterns without addressing the implications for pharmacotherapy or toxicology is waning, as the field moves towards more analytical and intervention-based research.

Similar Journals

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY

Pioneering Discoveries in Pharmacology and Physiology
Publisher: WILEYISSN: 0305-1870Frequency: 12 issues/year

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, published by WILEY, is a premier journal that serves as a vital resource for researchers, professionals, and students in the fields of pharmacology and physiology. With ISSN 0305-1870 and E-ISSN 1440-1681, this journal has established itself as a significant contributor to scientific dialogue since its inception in 1974. Currently spanning until 2024, it consistently publishes cutting-edge research addressing both experimental and clinical advancements in pharmacology and physiology. Recognized for its quality, it holds a Q2 ranking in the 2023 Pharmacology category and notable Q3 rankings in both Physiology and Medical Physiology. The journal's coverage of topical issues not only ensures a robust platform for innovative findings but also fosters collaborations across disciplines. Although not an Open Access journal, its curated content is invaluable for advancing knowledge, as evidenced by its solid Scopus rankings, which place it within the top percentiles of its field. Engaging with this journal means staying at the forefront of research that shapes clinical practices and experimental methodologies.

BIOLOGICAL & PHARMACEUTICAL BULLETIN

Fostering Excellence in Biomedical and Pharmaceutical Discourse
Publisher: PHARMACEUTICAL SOC JAPANISSN: 0918-6158Frequency: 12 issues/year

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

DARU-Journal of Pharmaceutical Sciences

Exploring the forefront of pharmacology and toxicology.
Publisher: SPRINGER INT PUBL AGISSN: Frequency: 2 issues/year

DARU-Journal of Pharmaceutical Sciences is a leading peer-reviewed journal published by SPRINGER INT PUBL AG that focuses on the dynamic and rapidly evolving fields of pharmaceutical sciences, including drug discovery, pharmacology, and toxicology. With an impressive Q2 ranking in both Drug Discovery and Miscellaneous Medicine categories for 2023, this journal stands out as a vital resource for researchers, professionals, and students alike, offering a platform for significant contributions to the scientific community. Covering a comprehensive scope from 2000 to 2024 and indexed by Scopus, the journal ranks within the top percentile in its field, with a ranking of #66/313 in Pharmacology and #34/157 in Drug Discovery, reaffirming its impact and relevance. The journal promotes open access to foster widespread dissemination of knowledge in pharmaceutical sciences, ultimately aiming to bridge the gap between research and clinical applications. For those looking to stay at the forefront of pharmaceutical innovation, DARU represents an invaluable connection to the latest studies and breakthrough findings.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Unlocking the Secrets of Drug Action and Efficacy
Publisher: AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICSISSN: 0022-3565Frequency: 12 issues/year

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.

Journal of Pharmacological Sciences

Exploring the frontiers of pharmacology and medicine.
Publisher: JAPANESE PHARMACOLOGICAL SOCISSN: 1347-8613Frequency: 12 issues/year

Journal of Pharmacological Sciences is a leading peer-reviewed academic journal dedicated to the field of pharmacology, published by the Japanese Pharmacological Society. Since its inception, this journal has offered an essential platform for the dissemination of high-quality research, contributing significantly to advancements in molecular medicine and pharmacology. With an impact factor that places it in the prestigious Q2 quartile for both categories, the journal has established itself as a credible source of innovative findings and methodologies since its transition to Open Access in 2015. This accessibility enables a broader audience, including researchers, healthcare professionals, and students, to engage with valuable insights and discussions pertinent to drug development, pharmacodynamics, and therapeutic strategies. Based in Kyoto, Japan, the journal serves as a vital resource for the global pharmacological community, encouraging collaboration and research that leads to improved health outcomes. For more information, submissions, and access to the latest research, visit the journal’s website.

European Journal of Pharmacology

Exploring the frontiers of therapeutic applications and drug development.
Publisher: ELSEVIERISSN: 0014-2999Frequency: 24 issues/year

The European Journal of Pharmacology, a prestigious publication by Elsevier, serves as a vital resource in the field of pharmacology, offering rich insights into drug development and therapeutic applications. Since its inception in 1967, this journal has evolved to encompass groundbreaking research, including pharmacokinetics, toxicology, and innovative pharmacological methodologies, making it an essential platform for researchers and professionals alike. With an impressive impact factor that places it in the Q1 category of pharmacological journals and a Scopus ranking of #49 out of 313, the journal is recognized in the 84th percentile within its category, solidifying its significance in the academic community. Although the journal is not open access, it continues to attract contributions from leading scientists worldwide, ensuring that cutting-edge findings are disseminated effectively. The European Journal of Pharmacology not only highlights advancements in drug discovery and clinical applications but also promotes interdisciplinary collaboration, ultimately contributing to the progress of healthcare globally.

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Connecting Researchers with Cutting-Edge Pharmacological Insights
Publisher: SPRINGERISSN: 0028-1298Frequency: 12 issues/year

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is a prestigious journal published by SPRINGER, focusing on the dynamic fields of pharmacology and toxicology. With an ISSN of 0028-1298 and an E-ISSN of 1432-1912, this esteemed publication has been a staple in the scientific community since its inception in 1969, continuing to wield influence with a convergence of research that reaches through 2024. Ranked in the Q2 category for both medicine and pharmacology, it stands at an impressive 111th out of 313 in the Scopus rankings for pharmacology, reflecting its significant impact in the field. Though not offering open access, the journal remains a vital resource for researchers, professionals, and students seeking to explore groundbreaking studies and advancements in pharmacological science. With its high standards and comprehensive coverage, NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY is essential reading for those dedicated to understanding the mechanisms of drug action and the complexities of therapeutic interventions.

SCIENTIA PHARMACEUTICA

Exploring new horizons in pharmaceutical research.
Publisher: MDPIISSN: Frequency: 4 issues/year

SCIENTIA PHARMACEUTICA, published by MDPI in Switzerland, is a leading open access journal dedicated to advancing the field of pharmaceutical sciences since 2006. With a focus on pharmacology, toxicology, and pharmaceutics, this journal plays a pivotal role in disseminating high-quality research and innovative findings. It boasts an impressive impact factor and is ranked in the second quartile (Q2) for Pharmaceutical Science, signifying its influence within the academic community, aided by a Scopus ranking of 74 out of 183 journals in the same category. SCIENTIA PHARMACEUTICA invites original research articles, reviews, and notes that contribute to the understanding and development of pharmaceutical science, making it an essential resource for researchers, professionals, and students alike seeking to stay at the forefront of this continuously evolving field. For those interested in broadening their knowledge and sharing insights, the journal ensures wide accessibility, supporting the open access model for maximum outreach.

PHARMAZIE

Pioneering insights in toxicology and pharmaceutics.
Publisher: AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBHISSN: 0031-7144Frequency: 12 issues/year

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

JOURNAL OF PHARMACY AND PHARMACOLOGY

Pioneering research for transformative healthcare solutions.
Publisher: OXFORD UNIV PRESSISSN: 0022-3573Frequency: 12 issues/year

Journal of Pharmacy and Pharmacology, published by Oxford University Press, is a prestigious academic journal dedicated to the advancement of knowledge in the fields of pharmaceutical sciences and pharmacology. With a strong heritage dating back to 1949, this journal maintains a robust influence, as evidenced by its ranking in the second quartile (Q2) across both Pharmaceutical Science and Pharmacology categories for 2023. The journal is accessible without an open access option, ensuring traditional academic engagement and providing valuable insights for researchers and professionals. It boasts an impressive Scopus ranking, with a percentile positioning of 72nd in Pharmaceutical Science and 67th in Pharmacology. Aimed at fostering innovative research and facilitating the exchange of cutting-edge scientific knowledge, the Journal of Pharmacy and Pharmacology serves as an essential resource for scientists, students, and healthcare professionals committed to enhancing therapeutic outcomes and advancing pharmaceutical innovations.